ATC Group: B06AX Other hematological agents

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B06AX in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B06 Other hematological agents
3 B06A Other hematological agents
4 B06AX Other hematological agents

Group B06AX contents

Code Title
B06AX01
B06AX02
B06AX03
B06AX04
B06AX05

Active ingredients in B06AX

Active Ingredient Description
Betibeglogene autotemcel

Betibeglogene autotemcel adds functional copies of a modified β-globin gene into the patients' HSCs through transduction of autologous CD34+ cells with BB305 LVV, thereby addressing the underlying genetic cause of the disease. After betibeglogene autotemcel infusion, transduced CD34+ HSCs engraft in the bone marrow and differentiate to produce RBCs containing biologically active βA-T87Q-globin (a modified β-globin protein) that will combine with α-globin to produce functional Hb containing βA-T87Q-globin (HbAT87Q).

Crizanlizumab

Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands including P-selectin glycoprotein ligand 1.

Exagamglogene autotemcel

Exagamglogene autotemcel is a cell therapy consisting of autologous CD34+ HSPCs ex vivo edited by CRISPR/Cas9-technology. The highly specific guide RNA enables CRISPR/Cas9 to make a precise DNA double-strand break at the critical transcription factor binding site (GATA1) in the erythroid specific enhancer region of the BCL11A gene. As a result of the editing, GATA1 binding is irreversibly disrupted and BCL11A expression reduced. Reduced BCL11A expression results in an increase in γ-globin expression and foetal haemoglobin (HbF) protein production in erythroid cells, addressing the absent globin in transfusion-dependent β-thalassemia (TDT) and the aberrant globin in sickle cell disease (SCD), which are the underlying causes of disease.

Related product monographs

Title Information Source Document Type  
ADAKVEO Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
CASGEVY Dispersion for infusion European Medicines Agency (EU) MPI, EU: SmPC
CASGEVY Suspension for infusion FDA, National Drug Code (US) MPI, US: SPL/PLR
OXBRYTA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
OXBRYTA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
PYRUKYND Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
ZYNTEGLO Dispersion for infusion European Medicines Agency (EU) MPI, EU: SmPC